You just read:

Protagonist Therapeutics Initiates Phase 1 Trial of Oral, Gut-Restricted, Alpha-4-Beta-7 Integrin Antagonist PN-10943

News provided by

Protagonist Therapeutics, Inc.

Dec 13, 2018, 07:00 ET